A Study of BGM0504 Tablets in Healthy Chinese Subjects

NCT07566572 | Recruiting Phase 1 FDA Drug

• 1 other identifier: BGM0504-CPK-102
• Study Type: interventional
• Target: 144
• Locations: 1 country
• Sites: 1

Brief Summary

A randomized, open-label, multiple-dose study to evaluate the effects of high-fat meals and different administration conditions (including water intake and fasting time) on the pharmacokinetics of BGM0504 tablets at a dose of 20mg in healthy Chinese participants and to assess its safety and tolerability.

Conditions

Chinese Healthy Volunteers

Outcome Measures

Primary Outcomes (3)

• Pharmacokinetic (PK) endpoint： AUC0-tau,ss

  4 weeks

• PK endpoint：Cmax,ss

  4 weeks

• PK endpoint：t1/2,ss

  4 weeks

Secondary Outcomes (5)

• Pharmacodynamics (PD) endpoint：Changes in fasting blood glucose

  6 weeks

• PD endpoint：waist circumference before and after administration

  6 weeks

• PD endpoint：body weight before and after administration

  6 weeks

• Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

  6 weeks

• Number of participants with treatment-related serious adverse events as assessed by CTCAE v4.0

  6 weeks

Study Arms (1)

BGM0504 tablets

EXPERIMENTAL

Oral administration once daily

Drug: BGM0504 tablets

Interventions

BGM0504 tablets DRUG

Administered p.o.

BGM0504 tablets

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• ○ Between the ages of 18 and 55 years (inclusive) at the time of screening, both male and female;
• weight ≥ 50 kg, and body mass index (BMI): 24.0 kg/m² ≤ BMI \< 30 kg/m²（BMI = weight/height²）;
• (Medical Inquiry) Have a stable body weight (\<5% self-reported change during the previous 12 weeks) before screening.
• Participants should be willing to take effective contraceptive measures from the date of signing the informed consent form until 3 months after the last administration, and have no plans for sperm or egg donation.
• Participants who were determined to be generally healthy by the investigator based on their past medical history, physical examination, vital signs, laboratory tests and electrocardiogram examinations.

You may not qualify if:

• ● (Medical Inquiry) Individuals with a history of severe drug allergies (especially known or suspected allergies to the components and excipients of BGM0504 tablets) or those with severe specific allergic diseases/diseases history or severe allergic constitution;
• (Medical Inquiry) Individuals who have previously suffered from or currently have major diseases in the nervous system, cardiovascular system, digestive system, respiratory system, urinary system, endocrine system, blood system or immune system, and are judged by the investigator to be unsuitable to participate in this trial;
• (Examination) Any laboratory test results judged by the investigator as abnormal and of clinical significance;
• (Medical Inquiry/Examination) Individuals who previously had obvious gastrointestinal diseases or related symptoms (such as nausea, vomiting, heartburn sensation or diarrhea), affected gastric emptying (such as pyloric stenosis), or had undergone any gastrointestinal surgery (except for intestinal polyp resection and appendectomy), or had acute diarrhea, constipation within the 7 days before randomization; Diarrhea is defined as watery stools and/or daily defecation ≥ 3 times. Constipation is defined as the inability to achieve at least one defecation per day;
• (Medical Inquiry/Examination) During the screening, individuals with acute cholecystitis, chronic cholecystitis; or those with symptomatic or treatable gallstones at the time of screening; or those with symptomatic or treatable gallbladder polyps at the time of screening;
• (Medical Inquiry) Individuals previously diagnosed with thyroid C-cell carcinoma, MEN (Multiple Endocrine Adenoma Disease) type 2A or 2B, or with a related family history;
• (Medical Inquiry) Individuals previously diagnosed with acute or chronic pancreatitis, or pancreatic injury;
• (Medical Inquiry/Query) Individuals who used any prescription drugs or over-the-counter drugs (including chemical drugs, vitamin drugs, herbal drugs, etc.) within 2 weeks before screening;
• (Examination) Individuals with any positive results for hepatitis B surface antigen, hepatitis C virus antibody, human immunodeficiency virus antibody, or Treponema pallidum antibody during the screening period;
• (Examination) At the screening/baseline, 12-lead electrocardiogram shows a heart rate of \< 50 beats per minute or \> 100 beats per minute, second or third degree atrioventricular conduction block, long QT syndrome or for women QTcF \> 470 ms or for men \> 450 ms or other electrocardiogram abnormalities judged by the investigator as requiring drug intervention;
• (Medical Inquiry) Individuals with a history of fainting during blood transfusion or needle phobia;
• (Medical Inquiry) Individuals who have taken drugs or had drug abuse history within 6 months before screening;
• (Medical Inquiry) Individuals who smoked more than 10 cigarettes per day on average (including nicotine replacement products) within 3 months before screening, or who could not prohibit smoking throughout the trial stay;
• (Medical Inquiry) Individuals who frequently drank alcohol within the 3 months before screening, that is, with an average daily alcohol intake of more than 2 units (1 unit = 17.7 mL ethanol, that is, 1 unit = 357 mL alcohol for 5% beer or 43 mL alcohol for 40% liquor or 147 mL alcohol for 12% wine) or who could not abstain from alcohol throughout the trial stay;
• (Medical Inquiry) Individuals who donated blood or lost more than 400 mL of blood within 3 months before screening or plan to donate blood during or after the trial;

Sponsors & Collaborators

• BrightGene Pharmaceutical (Suzhou) Co., LTD: collaborator
• BrightGene Bio-Medical Technology Co., Ltd.: lead

Study Sites (1)

Hangzhou First People's Hospital

Hangzhou, Zhejiang, 310006, China

RECRUITING

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 22, 2026
• First Posted: May 5, 2026
• Study Start: March 26, 2026
• Primary Completion (Estimated): September 30, 2026
• Study Completion (Estimated): September 30, 2026
• Last Updated: May 5, 2026

Record last verified: 2026-04

Locations

CN (1)